Precision Medicine in Severe Asthma: The Importance of Phenotypes and Endotypes in Patient Evaluation

Friday, September 13, 2019, 12:00 PM - Sunday, September 13, 2020, 11:59 PM

AMA PRA Category 1 Credits™ (0.50 hours), ABIM MOC Part 2 (0.50 hours), AMA PRA Category 1 Credits™ Designated (0.50 hours)

Severe asthma affects only 3-6% of the overall population of asthmatics, but accounts for nearly half of the annual expenditures among asthma patients. Advances in the understanding of the pathophysiology of severe asthma have led to the identification of specific asthma endotypes and phenotypes that may be used to better tailor therapy in the future. This activity will explore the value of determining patient endotypes and phenotypes and review biomarker testing that can help clinicians appropriately classify severe asthma patients.

There are no fees for participating in and receiving CME credit for this online activity.

To participate in this program, click here.

1. Identify the characteristics of uncontrolled, difficult-to-treat, and severe asthma;
2. Describe how the pathophysiology of asthma produces distinct disease phenotypes/endotypes for characterization of severe asthma;
3. Summarize clinical, laboratory, and other diagnostic findings that are consistent with each phenotype/endotype of severe asthma to improve treatment selection and asthma control.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

American Board of Internal Medicine

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Faculty & Disclosure / Conflict of Interest Policy

According to the disclosure policy of the University of Cincinnati College of Medicine, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interest related to this activity. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosure will be made at the time of activity.

Medical Director & Program Planners

MCM Education
Scott Korber, Medical Writer
Linda Hopkins, Project Manager
Mary Ledwith, VP Medical Education, Grant Management

University of Cincinnati Continuing Medical Education Office
Bruce Gebhardt, MD
Susan P. Tyler, MEd, CMP, CHCP, Director
Heather Muskopf, Program Manager

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati College of Medicine nor MCM Education, recommends the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati College of Medicine or MCM Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement
The opinions expressed during this educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees; professional development.

Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

This activity is supported by educational grants from Sanofi Genzyme and Regeneron Pharmaceuticals and Novartis Pharmaceutical Corporation.